Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Nivolumab plus Gemcitabine/Platinum for Muscle-Invasive or Locally-Advanced Bladder Urothelial Carcinoma
KCT0003804Phase 2Completed
- Sponsor
- Samsung Medical Center
- Start
- Jun 2019
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab and gemcitabine in transitional cell carcinoma of the bladder (TCC), sponsored by Samsung Medical Center. Started Jun 2019; status: completed.
02
Drugs
nivolumabgemcitabine
03
Conditions
transitional cell carcinoma of the bladder (TCC)
Beyond the preview
Go deeper on KCT0003804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003804.